Target Audience

This program is designed for hematologists/oncologists, dermatologists, researchers, physician assistants, nurses and students.

Learning Objectives: General Sessions

At the conclusion of this activity, attendees should be better able to:

  • Describe new screening, diagnostic, and surveillance techniques, as well as the follow-up of patients with early melanoma using the latest technologies.
  • State the role of complete node dissections for microscopic nodal disease based on current evidence that assesses the clinical utility of sentinel node mapping in the management of malignant melanoma.
  • Assess the current state of adjuvant therapy and options that may be available in the future.
  • Compare the advantages and limitations of intralesional, locoregional and systemic interventions for treatment of advanced cutaneous malignancies.
  • Assess unique clinical situations such as brain metastases, Merkel cell carcinoma, mucosal melanoma, and uveal melanoma and determine appropriate treatment approaches.
  • Examine recent evidence about basal cell carcinomas and the management of cutaneous t-cell lymphomas and aggressive squamous cell carcinomas.
  • Review potential benefits and adverse effects of emerging therapeutic agents for the treatment of primary cutaneous malignancies.
  • Obtain an understanding of the role of currently available and potential future applications of immunotherapy and targeted therapy for advanced melanoma.
  • Analyze outcomes from investigative clinical trials that involve the use of adjuvant therapy and novel biologics for the treatment of high risk melanoma.
  • Determine how to best utilize the various biomarkers and molecular testing to determine prognosis and optimize care for patients with melanoma.
  • Evaluate the potential positive impact that interdisciplinary approaches to melanoma treatment may have on patient outcomes.
  • Analyze potential algorithms for the treatment of advanced melanomas, using newly approved agents, to assist in therapeutic decision making.
  • Examine emerging clinical challenges regarding melanoma care.

Learning Objectives: Saturday Breakfast Program

  • Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors as both mono and combination therapy for the management of advanced melanoma.
  • Review common immune-related adverse events as well as a multidisciplinary approach for their identification and management.
Meeting organized by
Association and Meeting Solutions
This continuing medical
education activity is provided by

Vindico Medical Education
Official media partnership with

HemOnc Today Melanoma 2017 is supported by educational grants from Bristol-Myers Squibb; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer, Inc.

HemOnc Today Melanoma 2017 is sponsored, in part, by Amgen; Bristol-Myers Squibb; Genentech; and Merck.

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: For the purpose of recertifying with the ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.